trial · primary record
[225Ac]Ac-AKY-2519 (therapeutic)
NSCLC
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 152 |
| Primary completion | 2033-12 |
| Primary endpoint | Part 1: Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519 |
| Registry ID | NCT07887971 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:54.369Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07887971
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- [225Ac]Ac-AKY-2519 (therapeutic) · compound